ASSEMBLY BIOSCIENCES, INC. (ASMB) — SEC Filings

Latest SEC filings for ASSEMBLY BIOSCIENCES, INC. (ASMB), explained in plain English.

Sentiment Overview: 1 bullish, 28 neutral, 2 mixed

Recent Filings (31)

• EFFECT Filing — EFFECT · 2026-03-30T00:15:19-04:00 [neutral]
• 8-K Filing — 8-K · 2025-12-08T00:00:00.000Z [neutral]
• Assembly Bio Narrows Q3 Loss, Secures $175M Funding Round — 10-Q · 2025-11-10T00:00:00.000Z [bullish] Risk: medium
  ASSEMBLY BIOSCIENCES, INC. reported a net loss of $9.196 million for the three months ended September 30, 2025, a slight improvement from the $9.613 million net
• Assembly Biosciences Files 8-K on Key Agreements and Equity Sales — 8-K · 2025-08-11T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed an 8-K on August 11, 2025, reporting on events that occurred on August 8, 2025. The filing indicates an entry into a material d
• Assembly Biosciences Files 8-K — 8-K · 2025-08-08T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed an 8-K on August 8, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
• Assembly Bio Narrows Q2 Loss to $28.7M Amid R&D Streamlining — 10-Q · 2025-08-06T00:00:00.000Z [mixed] Risk: high
  ASSEMBLY BIOSCIENCES, INC. reported a net loss of $28.7 million for the three months ended June 30, 2025, a decrease from the $30.1 million net loss for the sam
• Assembly Biosciences Files 8-K — 8-K · 2025-06-25T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed an 8-K on June 25, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific
• Assembly Biosciences Reports Director/Officer Changes & More — 8-K · 2025-06-09T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed an 8-K on June 9, 2025, reporting on events that occurred on June 5, 2025. The filing covers the departure of directors or cert
• Assembly Biosciences Files Q1 2025 10-Q — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business
• Assembly Biosciences Executive Compensation Details — DEF 14A · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed a DEF 14A on April 23, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes
• Assembly Biosciences Files 2024 10-K, Cites Gilead Deal — 10-K · 2025-03-20T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Ventrus
• Assembly Biosciences Files 8-K — 8-K · 2025-02-20T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed an 8-K on February 20, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain spec
• Assembly Biosciences Files 8-K on Material Agreement — 8-K · 2025-01-03T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed an 8-K on January 3, 2025, reporting a material definitive agreement and a direct financial obligation entered into on December
• Assembly Biosciences Files 8-K — 8-K · 2024-12-26T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed an 8-K on December 26, 2024, reporting other events and financial statements. The company, formerly known as Ventrus Bioscience
• Assembly Biosciences Files 8-K on Material Agreement — 8-K · 2024-12-19T00:00:00.000Z [neutral] Risk: medium
  On December 19, 2024, Assembly Biosciences, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equ
• Assembly Biosciences Files 8-K with Corporate Updates — 8-K · 2024-12-13T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed an 8-K on December 12, 2024, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements an
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• Assembly Biosciences Files Q3 2024 10-Q — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position and operations, includin
• Assembly Biosciences Files 8-K — 8-K · 2024-09-23T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed an 8-K on September 23, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain spe
• Assembly Biosciences Q2 2024: Cash Down, Arbutus Deal Details — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $200.6 million as of June 30, 2
• Schornstein Amends Stake in Assembly Biosciences — SC 13D/A · 2024-06-24T00:00:00.000Z [neutral] Risk: medium
  Alexander Schornstein filed an amendment (Amendment No. 3) to Schedule 13D on June 24, 2024, regarding Assembly Biosciences, Inc. The filing indicates a change
• Gilead Sciences Amends Filing for Assembly Biosciences Stake — SC 13D/A · 2024-06-20T00:00:00.000Z [neutral] Risk: medium
  Gilead Sciences, Inc. filed an amendment (No. 1) to its Schedule 13D on June 20, 2024, regarding Assembly Biosciences, Inc. The filing indicates a change in ben
• Assembly Biosciences Enters Material Agreement — 8-K · 2024-06-18T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. announced on June 16, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of
• Assembly Biosciences Ditches HBV Program, Cuts 45% Workforce — 8-K · 2024-06-03T00:00:00.000Z [mixed] Risk: high
  Assembly Biosciences, Inc. announced on May 29, 2024, a strategic decision to discontinue its Hepatitis B virus (HBV) program, including its lead drug candidate
• Assembly Biosciences Files Q1 2024 10-Q — 10-Q · 2024-05-08T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. filed a 10-Q for the period ending March 31, 2024. The company reported financial results and provided updates on its business operat
• Assembly Biosciences: Executive Compensation & Stock Awards Detailed — DEF 14A · 2024-04-17T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed a DEF 14A on April 17, 2024, detailing executive compensation and stock awards. The filing covers adjustments to stock and opti
• Assembly Biosciences Files 8-K on Operations — 8-K · 2024-03-28T00:00:00.000Z [neutral] Risk: low
  Assembly Biosciences, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition, as well as financial statements and e
• Assembly Biosciences Appoints New CEO, CMO, CFO — 8-K · 2024-03-15T00:00:00.000Z [neutral] Risk: medium
  Assembly Biosciences, Inc. announced on March 12, 2024, a series of significant leadership changes. Dr. Henry "Hank" Alfred, Jr. has been appointed as the new C
• Assembly Biosciences Reports Bylaw & Security Holder Rights Changes — 8-K · 2024-02-13T00:00:00.000Z [neutral] Risk: medium
  ASSEMBLY BIOSCIENCES, INC. filed an 8-K on February 13, 2024, reporting events that occurred on February 8, 2024. The filing indicates material modifications to
• ASMB Files 8-K on Shareholder Vote & Other Events — 8-K · 2024-02-02T00:00:00.000Z [neutral]
  Assembly Biosciences, Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on January 31, 2024. This filing indicates that the company submit
• ASMB Terminates Material Agreement, Signals Strategic Shift — 8-K · 2024-01-17T00:00:00.000Z [neutral]
  Assembly Biosciences, Inc. (ASMB) filed an 8-K on January 17, 2024, reporting the termination of a material definitive agreement, effective January 11, 2024. Th